Azithromycin carries cardiovascular risks that prompted FDA labeling changes advising against its use in patients with known risk factors like QT-interval prolongation or bradycardia.
FDA labeling changes advise against azithromycin use in patients with specific cardiovascular risk factors due to potential cardiovascular risks.
Absolute Event Rate: 0% vs 0%
The FDA recently approved labeling changes advising against the use of azithromycin in patients with known cardiovascular risk factors such as QT-interval prolongation, hypokalemia, hypomagnesemia, bradycardia, or use of class IA or class III antiarrhythmic agents.
Mosholder et al. (Thu,) reported a other. Azithromycin carries cardiovascular risks that prompted FDA labeling changes advising against its use in patients with known risk factors like QT-interval prolongation or bradycardia.